Brain levels of neuropeptides in human chronic methamphetamine users.
Animal data show that neuropeptide systems in the dopamine-rich brain areas of the striatum (caudate, putamen, and nucleus accumbens) are influenced by exposure to psychostimulants, suggesting that neuropeptides are involved in mediating aspects of behavioral responses to drugs of abuse. To establish in an exploratory study whether levels of neuropeptides are altered in brain of human methamphetamine users, we measured tissue concentrations of dynorphin, metenkephalin, neuropeptide Y, neurotensin, and substance P in autopsied brains of 16 chronic methamphetamine users and 17 matched control subjects. As expected, levels of most neuropeptides were enriched in dopamine-linked brain regions such as the nucleus accumbens and striatum of normal human brain. In contrast to animal findings of increased neuropeptide levels following short-term methamphetamine exposure, striatal neuropeptide concentrations were either normal or moderately decreased in the methamphetamine users. In other examined dopamine-poor cortical and subcortical brain areas, neuropeptide levels were generally either normal or variably reduced. Although the neuropeptide differences might be explained by methamphetamine-induced damage to neuropeptide-containing neurons, our human data are consistent with the possibility that, at least in the human striatum, long-term methamphetamine exposure leads to an adaptive process that is distinct from that which increases neuropeptide levels after acute methamphetamine exposure.
Frankel
Paul S
PS
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA. paul.frankel@pharm.utah.edu
Alburges
Mario E
ME
Bush
Lloyd
L
Hanson
Glen R
GR
Kish
Stephen J
SJ
D000328:Adult; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008694:Methamphetamine; D009479:Neuropeptides / Q000378:metabolism*; D011180:Postmortem Changes; D011863:Radioimmunoassay / Q000379:methods; D018709:Statistics, Nonparametric; D019966:Substance-Related Disorders / Q000209:etiology / Q000378:metabolism / Q000473:pathology*
D009479:Neuropeptides; D008694:Methamphetamine
J Neurochem. 2000 May;74(5):2120-6
10800957
Forensic Sci Int. 2001 Feb 15;116(2-3):163-9
11182268
J Neurochem. 2001 Feb;76(3):721-9
11158242
Neuroscience. 2001;102(4):843-51
11182247
Am J Psychiatry. 2001 Mar;158(3):377-82
11229977
Curr Mol Med. 2002 Nov;2(7):667-76
12420805
Psychol Med. 2003 Nov;33(8):1407-14
14672249
Brain. 2004 Feb;127(Pt 2):363-70
14645148
Eur J Pharmacol. 1991 Feb 14;193(3):367-70
1675997
Trends Neurosci. 1992 Apr;15(4):133-9
1374971
Neuropeptides. 1992 Jul;22(3):175-83
1436404
Eur J Pharmacol. 1992 Nov 3;222(1):7-12
1361442
Synapse. 1993 Apr;13(4):357-69
7683144
Neuroscience. 1993 Aug;55(3):833-47
8105419
Eur J Pharmacol. 1994 Jan 14;251(2-3):191-9
7908639
Nat Med. 1996 Jun;2(6):699-703
8640565
Biol Pharm Bull. 1996 Mar;19(3):369-74
8924903
J Pharmacol Exp Ther. 1996 Aug;278(2):547-54
8768703
Brain Res. 1996 May 20;721(1-2):196-203
8793101
Brain Res Bull. 1997;42(3):211-9
8995332
Exp Neurol. 1998 Jul;152(1):41-9
9682011
Exp Brain Res. 1998 Nov;123(1-2):60-76
9835393
J Pharmacol Exp Ther. 1999 Mar;288(3):1160-6
10027854
Mol Psychiatry. 1999 Jan;4(1):26-32
10089005
Neuropsychopharmacology. 1999 Jun;20(6):565-81
10327426
Am J Psychiatry. 2005 Aug;162(8):1403-13
16055761
Eur J Pharmacol. 2005 Oct 17;522(1-3):47-54
16199030
Biol Psychiatry. 2005 Nov 15;58(10):770-8
16095568
Nat Neurosci. 2006 Feb;9(2):205-11
16415864
Neuropharmacology. 2000 Jul 24;39(10):1880-92
10884569
J Neurochem. 2004 Jun;89(6):1396-408
15189342
J Forensic Sci. 2004 Sep;49(5):1106-12
15461119
Nature. 1981 May 7;291(5810):73-6
7231526
Psychopharmacology (Berl). 1982;78(1):76-80
6815700
Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(1):91-5
2581284
J Pharmacol Exp Ther. 1987 May;241(2):443-7
3572804
J Biol Chem. 1988 Feb 5;263(4):1719-25
3276675
Eur J Pharmacol. 1988 Mar 15;147(3):411-20
2454197
Eur J Pharmacol. 1988 Oct 11;155(1-2):11-8
2907484
J Comp Neurol. 1990 May 15;295(3):339-69
1693632